Novellus
OverviewSuggest Edit
Novellus is an engineered cellular medicine company. It combines its patented gene editing and cell reprogramming technologies. The company serves patients with such diseases as AAT deficiency, Parkinson's, Crohn's disease, dystrophic epidermolysis bullosa, etc.
| Type | Private | |
| Founded | 2015 | |
| HQ | Cambridge, MA, US | Map |
| Website | novellus-inc.com | |
| Employee Ratings |
Recent NewsAll News
- Brooklyn ImmunoTherapeutics Announces Filing of Registration Statement for Proposed Secondary Offering of Shares Issued in Previously Announced Novellus Acquisition
- Brooklyn ImmunoTherapeutics Completes Acquisition of Novellus Therapeutics
- Brooklyn ImmunoTherapeutics Executes Letter of Intent to Acquire Novellus Therapeutics
- Lam Research Corporation Announces Notice of Full Redemption of 2.625% Senior Convertible Notes Due 2041 of Novellus Systems, Inc.
Latest Updates
| Employees (est.) (Sept 2021) | 15 | (-6%) |
| Cybersecurity rating | A | More |
Novellus Office Locations
Novellus has an office in Cambridge
Cambridge, MA, US (HQ)
1035 Cambridge St #17b
Novellus Financials and Metrics
Summary Metrics
Founding Date | 2015 |
Novellus Cybersecurity Score
Novellus Online and Social Media Presence
Novellus's Trends
Novellus News and Updates
November 19, 2021
Brooklyn ImmunoTherapeutics Announces Filing of Registration Statement for Proposed Secondary Offering of Shares Issued in Previously Announced Novellus Acquisition
NEW YORK, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq: BTX) (“Brooklyn”) today announced that on November 18, 2021 it filed with the Securities and Exchange Commission a registration statement on Form S-1 relating to the proposed public offering by certain selling s…
July 19, 2021
Brooklyn ImmunoTherapeutics Completes Acquisition of Novellus Therapeutics
Acquisition Advances Transformation Into Platform Company Focused on Cell, Gene Editing and Cytokine Therapy
June 14, 2021
Brooklyn ImmunoTherapeutics Executes Letter of Intent to Acquire Novellus Therapeutics
Novellus Therapeutics develops next-generation mesenchymal stem cell products using licensed patented mRNA cell reprogramming and gene editing technologies Novellus Therapeutics develops next-generation mesenchymal stem cell products using licensed patented mRNA cell reprogramming and gene editing t…
March 26, 2021
Lam Research Corporation Announces Notice of Full Redemption of 2.625% Senior Convertible Notes Due 2041 of Novellus Systems, Inc.
FREMONT, Calif., March 26, 2021 (GLOBE NEWSWIRE) -- Lam Research Corporation (Nasdaq: LRCX) today announced that it has issued a notice of redemption, on behalf of its subsidiary Novellus Systems, Inc. (“Novellus”), for all of the 2.625% Senior Convertible Notes due 2041 issued by Novellus (CUSIP …
October 13, 2020
Novellus Therapeutics Exclusively Licenses Induced Mesenchymal Stem Cells (iMSCs) to NoveCite for COVID-19 Related Acute Respiratory Distress Syndrome (ARDS) and Other Acute Respiratory Conditions
CAMBRIDGE, Mass., Oct. 13, 2020 /PRNewswire/ -- Novellus Therapeutics ("Novellus"), an engineered cellular medicines company, announced today that it has licensed its induced mesenchymal stem cells (iMSCs) on a worldwide basis to NoveCite, Inc., a newly formed subsidiary of Citius...
Novellus Frequently Asked Questions
When was Novellus founded?
Novellus was founded in 2015.
How many employees does Novellus have?
Novellus has 15 employees.
Who are Novellus competitors?
Competitors of Novellus include Nuclera, Editas Medicine and Creyon Bio.
Where is Novellus headquarters?
Novellus headquarters is located at 1035 Cambridge St #17b, Cambridge.
Where are Novellus offices?
Novellus has an office in Cambridge.
How many offices does Novellus have?
Novellus has 1 office.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies